EpiPen-maker Mylan reached a $465 million settlement with the Justice Department to "resolve questions that have been raised" about whether the Medicaid program overpaid for the lifesaving allergy injection, the company said in a release Friday afternoon.
In recent weeks, many politicians have called for investigations into whether EpiPen was improperly classified in the Medicaid Drug Rebate program. Under the rebate program, the EpiPen has been classified as a "non-innovator drug," which means the company is required to pay only a 13 percent rebate. In contrast, brand name or drugs with a single source must pay a 23.1 percent rebate and an additional amount if price hikes occurred faster than inflation.
